Metanomics Health launches energy metabolite platform
21 July 2011
Metanomics Health GmbH, a Berlin based BASF Group company, has announced the official launch of its
new Energy Metabolite Platform. This targeted platform maps key
metabolites affecting the energy status of a biological system.
Metanomics Health GmbH, offers non-targeted and targeted metabolite profiling to
healthcare customers.“The Energy Metabolite Platform ideally
complements our existing targeted platforms covering hormones,
eicosanoids and lipids, strengthening our technology leadership
position in metabolomics. The current method is applicable to
cellular sample types covering more than 70 mainly polar metabolites
relevant in the energy metabolism and has been further developed for
application in clinical studies based on full blood sampling,” said
Tim Boelke, Managing Director of Metanomics Health GmbH.
The value of the new method has been demonstrated in a set of in
vitro experiments and published linking energy metabolism to
dysfunctions in mitochondrial respiration. In particular, metabolite
profiling was capable of differentiating between mechanisms that impede
ATP formation via electron transport phosphorylation.
“Besides demonstrating its utility in toxicology applications, the
new energy platform ties in perfectly with processes of high relevance
in the area of oncology drug therapy and mechanism of action studies,”
stated Tim Boelke. “We see high potential for a broad usage in these
areas due to the specific strengths of the energy platform elucidating
the impact of new chemical entities (NCE) on the nucleotide pool.”
Metanomics Health is systematically expanding its technology and
product portfolio for the healthcare industry. Just three months ago
Metanomics Health announced the scientific and economic certification
program for MetaMap® Tox, a platform that uses metabolite patterns for
early recognition of NCE toxicity by DSEC (Drug Safety Executive
Council) a pre-competitive consortium of leading biopharmaceutical
companies.
“Our unique combination of broad profiling and targeted metabolite
platforms in biomarker discovery and validation is key in providing
actionable results to our industry partners. As such the new Energy
Metabolite Platform is a further example how Metanomics Health enables
its customers in core areas of product development”
Source: Metanomics Health